Beyondspring Inc (NASDAQ:BYSI) Stock Soars: H.C. Wainwright Upgardes With $100 PT
Shares of Beyondspring Inc (NASDAQ:BYSI) soared 170% to $26.06 after the company announced positive topline data of DUBLIN-3 trial in plinabulin in combination with docetaxel (DP) to treat 2nd and 3rd line NSCLC (EGFR wild type) compared to docetaxel alone (D) (n=559). H.C. Wainwright upgrades BYSI to Buy from Neutral and sets target price at $100. Analyst Joseph Pantginis said, “Dublin-3 provides some beautiful summer fireworks with endpoints met, representing…